Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome

Rev Esp Cardiol (Engl Ed). 2020 May;73(5):376-382. doi: 10.1016/j.rec.2019.06.014. Epub 2019 Nov 6.
[Article in English, Spanish]

Abstract

Introduction and objectives: Optimal lipid control is difficult to attain. We assessed preadmission achievement of the European Society of Cardiology targets for low-density lipoprotein-cholesterol (LDL-C) control in patients admitted for acute coronary syndrome.

Methods: Fasting LDL-C levels were measured in 3164 patients admitted between 2010 and 2017. We assessed the frequency of adequate LDL-C control, with targets defined according to individual cardiovascular risk, and the predictors of inadequate control.

Results: The median LDL-C value was 104 (80-130) mg/dL. Most patients had high or very high cardiovascular risk and only 34.2% had LDL-C levels below the recommended target for their estimated risk. Achievement of LDL-C goals increased moderately throughout the study period. Adequate LDL-C control was inversely associated with patient risk. Dyslipidemia, active smoking, diabetes mellitus, and body mass index ≥ 25 were independent predictors of inadequate lipid control, while ongoing statin therapy was associated with adequate control.

Conclusions: Only slightly more than one third of patients admitted for acute coronary syndrome meet recommended LDL-C targets on admission. There is broad scope for improvement in primary and secondary prevention, especially among patients who are overweight or have other cardiovascular risk factors.

Keywords: Acute coronary syndrome; Cardiovascular risk; Cholesterol; Colesterol; Estatinas; Lipids; Lípidos; Riesgo cardiovascular; Statins; Síndrome coronario agudo.

MeSH terms

  • Acute Coronary Syndrome / blood
  • Acute Coronary Syndrome / diagnosis*
  • Aged
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / therapeutic use*
  • Cholesterol, LDL / blood*
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / epidemiology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Lipids / blood
  • Male
  • Medication Adherence*
  • Middle Aged
  • Risk Factors
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids